Shanghai MicroPort MedBot (2252) Announces Updated Nomination Committee Terms

Bulletin Express11-25

Shanghai MicroPort MedBot (Group) Co., Ltd. (Stock Code: 2252) recently issued revised Terms of Reference for its Nomination Committee. According to the document, the Nomination Committee comprises at least three directors, with over half being independent non-executive directors, and includes at least one member of a different gender. The committee is tasked with identifying director and senior management candidates, recommending appointments and reappointments, and regularly reviewing board structure, composition, and diversity.

The Terms of Reference highlight detailed procedures for selecting directors and senior management, including the requirement to gather comprehensive information on candidates and obtain their consent before proceeding with nominations. The committee also evaluates the independence of independent non-executive directors and reviews succession plans for key leadership positions, particularly the chairman and chief executive officer.

Additionally, the Terms of Reference outline meeting protocols, requiring the Nomination Committee to convene at least once annually, with the flexibility to hold additional sessions as needed. The committee is authorized by the board to obtain independent professional advice and resources where necessary and must keep the board fully informed of all decisions and recommendations. The updated Terms of Reference come into effect upon approval by the board and supersede any previous version.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment